BAY-405 / Bayer, German Cancer Research Center - LARVOL DELTA

Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer. (PubMed, J Med Chem) - "Treatment of tumor-bearing mice shows T-cell-dependent antitumor efficacy. MAP4K1 inhibition in conjunction with PD-L1 blockade results in a superior antitumor impact, illustrating the complementarity of the single agent treatments."

Journal • Oncology • TGFB1

Bayer to Present New Clinical Data in Indolent non-Hodgkin’s Lymphoma and Additional Research on its Oncology Portfolio at AACR Annual Meeting 2021 (Businesswire) - “Bayer will also reveal the latest data from its differentiated early pipeline across other focus areas, including precision molecular oncology and immuno-oncology. For the first time, Bayer will be presenting preclinical data on investigational small molecule epidermal growth factor receptor (EGFR) exon 20 inhibitor BAY 2476568…In the area of immuno-oncology, Bayer will showcase preclinical findings on investigational oral small molecule inhibitor BAY-405, which is thought to target the intracellular immune checkpoint MAP4K1 (HPK1), jointly developed in the strategic research alliance with the German Cancer Research Center (DKFZ) in Heidelberg, Germany.”

EGFR exon 20 • Preclinical • Oncology

[VIRTUAL] Enhancement of anti-tumor T-cell immunity by means of an oral small molecule targeting the intracellular immune checkpoint MAP4K1 (AACR 2021) - "We developed the small molecule inhibitor BAY-405 that displays potent nanomolar MAP4K1 inhibition in biochemical and cellular assays, good kinase selectivity, and in vivo exposure after oral dosing...Moreover, we found that MAP4K1 is expressed in both PD-L1-high and PD-L1-low human cancers. In summary, our data show that selective inhibition of MAP4K1 by means of small molecule drugs may be used to expand the patient population responding to immune checkpoint inhibition."

Oncology • CD4 • CTLA4 • PD-1 • TGFB1